San Francisco I-bank ThinkEquity Partners is out with its latest air max 270 pas cher healthcare newsletter, and it’s rife with interesting tid bits. In public equity, ATS Medical, which makes cardiac surgery products, announced on March 16 that it has entered into definitive agreements with certain institutional investors for the private placement of approximately 8,125,000 shares of common stock at $2.00 per share, together with warrants to purchase approximately 3,250,000 shares at an exercise price of $2.40 per share. ATS intends to use the proceeds, which will gross approximately $16.25 million, for working capital and general corporate purposes. RBC Capital Markets acted as the sole placement agent for the offering. Read on for transactions involving Stereotaxis, Neose Technologies, ProteoGenix, SmoothShapes and Tripos.
Stereotaxis announced on March 16, that it has received commitments from certain investors to purchase 1,919,000 newly issued shares of its common stock at air max 270 pas cher a price of $10.50 per share pursuant to an effective registration statement. Under the terms of this transaction, the company expects to receive net proceeds of approximately $20.1 million after deducting offering expenses.
On March 13, Neose Technologies closed its previously announced private placement. The company sold 21,415,447 shares of common stock and warrants to purchase 9,636,950 shares of its common stock at a price of $2.02 per unit. Each unit consists of one share of common stock and a warrant to purchase 0.45 shares of common stock. The warrants have a term of five years and an exercise price of $1.96 per share. The company realized gross proceeds of approximately $43.3 million. Both new and existing investors participated in the private placement.
In private equity, New Leaf Venture Partners and TPG Growth announced on March 16 that they are co-leading a $20 million Series B private equity financing in ProteoGenix, Inc. Burrill & Company is also participating in the air max 270 pas cher financing. ProteoGenix applies innovative and proprietary genomic and high-throughput protein analytical techniques to develop diagnostic tests for maternal-fetal health. These next-generation molecular diagnostics will improve the quality of clinical decisions, resulting in better outcomes for mothers and newborns, as well as reducing expenditures and risk.
SmoothShapes, an emerging aesthetics company based in Merrimack, NH, announced on March 13 that it has raised $15 million in a Series B financing led by Portola Valley, CA-based Three Arch Partners, a venture capital firm with over $1 billion under management. The funds will be used to support the worldwide launch of the company’s first product, the SmoothShapes 100 System, an FDA-cleared combination therapy that uses lasers at predetermined wavelengths in the visible and infrared spectrums with vacuum massage to effect the air max 270 pas cher treatment of cellulite. Mark Wan, founding partner of Three Arch Partners, and Michael Ellwein, former executive vice president of Medtronic who has joined Three Arch as a venture partner, will join SmoothShapes’ board of directors.
In the M&A department, Tripos announced on March 16 that its proposals to sell the assets of its Discovery Informatics business to Vector Capital and to adopt a plan of dissolution and liquidation of the company following completion of that sale were each approved by the required stockholder vote. Liquidation of the company will occur following resolution of all corporate debts and obligations, and will commence approximately six months from now.http://www.kanyewestyeezy.fr